ArticleBMC cancer2022

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.

C Martínez-Laperche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.